U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C22H26O4
Molecular Weight 354.4394
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SERATRODAST

SMILES

CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O

InChI

InChIKey=ZBVKEHDGYSLCCC-UHFFFAOYSA-N
InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)

HIDE SMILES / InChI

Description

Seratrodast belongs to a class of medication called thromboxane A2/prostaglandin endoperoxide receptor antagonist. Seratrodast blocks the broncho-constrictor effects of certain chemicals (prostaglandins) in the body. Seratrodast also decreases the inflammation by antagonising the thromboxane A2 receptor. Adverse effects include gastrointestinal disturbances, drowsiness, headache, palpitations, and hepatitis. Seradair may interact with Ozagrel.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
60.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Bronica

PubMed

Sample Use Guides

In Vivo Use Guide
It is given in single doses of 80 mg in the evening after food.
Route of Administration: Oral
In Vitro Use Guide
Seratrodast competitively inhibited the contractile response to U-46619, PGD2, 9-alpha, 11beta-PGF2, or PGF2-alpha with pA2 values of 7.69, 7.20, 7.79, and 5.71, respectively.